Literature DB >> 19432863

Longterm follow-up of diode laser transscleral cyclophotocoagulation in the treatment of refractory glaucoma.

Paolo Frezzotti1, Vincenzo Mittica, Gianluca Martone, Ilaria Motolese, Luca Lomurno, Sabrina Peruzzi, Edoardo Motolese.   

Abstract

PURPOSE: This prospective study was conducted to evaluate the efficacy and safety of transscleral diode laser cyclophotocoagulation (TDLCP) in advanced refractory glaucoma.
METHODS: A total of 124 eyes in 121 patients with advanced glaucoma refractory to medical treatment were treated consecutively with TDLCP. Success was defined as final intraocular pressure (IOP) of 5-21 mmHg in eyes with visual acuity (VA) of more than hand movements (HM) and relief of pain in eyes with VA of HM or less, including blind eyes.
RESULTS: Mean patient age was 65.6 +/- 17.1 years (range 14-91 years). Mean follow-up was 17 +/- 14.6 months (range 3-42 months). Mean pretreatment IOP was 29.9 +/- 8.4 mmHg (range 17-58 mmHg) and IOP at last follow-up was 20.8 +/- 8 mmHg (range 6-45 mmHg) (p < 0.001). The number of laser applications (mean 9.2 +/- 2.8, range 4-15) and maximal laser power (mean 2.01 +/- 0.22 mW, range 1.3-3.0 mW) were not associated with lower postoperative IOP. Intraocular pressure of < or = 21 mmHg was recorded in 63.0% of eyes at the last follow-up visit. Overall, 28 (21.7%) eyes required at least one retreatment. No phthisis bulbi or persistent hypotonia developed.
CONCLUSIONS: TDLCP is an effective and safe method for the treatment of advanced refractory glaucoma, although repeated treatments are often necessary.

Entities:  

Mesh:

Year:  2009        PMID: 19432863     DOI: 10.1111/j.1755-3768.2008.01354.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  9 in total

1.  Intermediate term safety and efficacy of transscleral cyclophotocoagulation after tube shunt failure.

Authors:  Peter J Ness; Mahmoud A Khaimi; Robert M Feldman; Rania Tabet; Steven R Sarkisian; Gregory L Skuta; Alice Z Chuang; Kimberly A Mankiewicz
Journal:  J Glaucoma       Date:  2012-02       Impact factor: 2.503

2.  Retrospective review on the outcome and safety of transscleral diode laser cyclophotocoagulation in refractory glaucoma in Chinese patients.

Authors:  Janice J C Cheung; Kenneth K W Li; Samuela W K Tang
Journal:  Int Ophthalmol       Date:  2017-12-11       Impact factor: 2.031

3.  Assessment of Scleral and Conjunctival Thickness of the Eye after Ultrasound Ciliary Plasty.

Authors:  Bartłomiej Bolek; Adam Wylęgała; Edward Wylęgała
Journal:  J Ophthalmol       Date:  2020-09-24       Impact factor: 1.909

Review 4.  Advanced glaucoma: management pearls.

Authors:  Girum W Gessesse; Karim F Damji
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Apr-Jun

Review 5.  Evolution of Cyclophotocoagulation.

Authors:  Jideofor K Ndulue; Kamran Rahmatnejad; Carina Sanvicente; Sheryl S Wizov; Marlene R Moster
Journal:  J Ophthalmic Vis Res       Date:  2018 Jan-Mar

6.  Observational report: Improved outcomes of transscleral cyclophotocoagulation for glaucoma patients.

Authors:  Rick Edward Bendel; Michael Ty Patterson
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

7.  Safety and effectiveness of primary transscleral diode laser cyclophotoablation for glaucoma in Nigeria.

Authors:  Mohammed M Abdull; David C Broadway; Jennifer Evans; Fatima Kyari; Fatima Muazu; Clare Gilbert
Journal:  Clin Exp Ophthalmol       Date:  2018-06-17       Impact factor: 4.207

8.  Comparison of Outcomes between Endoscopic and Transcleral Cyclophotocoagulation.

Authors:  Robert Beardsley; Simon K Law; Joseph Caprioli; Anne L Coleman; Kouros Nouri-Mahdavi; Jean-Pierre Hubschman; Steven D Schwartz; JoAnn A Giaconi
Journal:  Vision (Basel)       Date:  2017-11-06

Review 9.  High-Intensity Focused Ultrasound Circular Cyclocoagulation in Glaucoma: A Step Forward for Cyclodestruction?

Authors:  Rodolfo Mastropasqua; Vincenzo Fasanella; Alessandra Mastropasqua; Marco Ciancaglini; Luca Agnifili
Journal:  J Ophthalmol       Date:  2017-04-22       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.